Multiple endocrine neoplasia type 2: an overview (Q28237010)

multiple endocrine neoplasia type 2

Europe PubMed Central

title

Multiple endocrine neoplasia type 2: an overview (English)

0 references

main subject

1 reference

2

Charis Eng

0 references

author name string

Jessica Moline

series ordinal

1

0 references

language of work or name

English

0 references

publication date

September 2011

0 references

published in

Genetics in Medicine

0 references

volume

13

0 references

issue

9

0 references

page(s)

755-64

0 references

cites work

Cancer phenomics: RET and PTEN as illustrative models

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Medullary thyroid cancer: management guidelines of the American Thyroid Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Pheochromocytoma in MEN 2A syndrome. Study of 54 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Germ-line mutations in nonsyndromic pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Guidelines for diagnosis and therapy of MEN type 1 and type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Identification of the Cys634-->Tyr mutation of the RET proto-oncogene in a pedigree with multiple endocrine neoplasia type 2A and localized cutaneous lichen amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Failure to recognize multiple endocrine neoplasia 2B: more common than we think?

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Early Malignant Progression of Hereditary Medullary Thyroid Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Recurrent or residual hyperparathyroidism and thyroid cancer effectively evaluated with scintigraphy

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Phaeochromocytoma, new genes and screening strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

A gene for Hirschsprung disease (megacolon) in the pericentromeric region of human chromosome 10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

A gene for Hirschsprung disease maps to the proximal long arm of chromosome 10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Mutations of the RET proto-oncogene in Hirschsprung's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

RET activation and clinicopathologic features in poorly differentiated thyroid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

One hundred and seven family members with the rearranged during transfection V804M proto-oncogene mutation presenting with simultaneous medullary and papillary thyroid carcinomas, rare primary hyperparathyroidism, and no pheochromocytomas: is this a

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Frequent association between MEN 2A and cutaneous lichen amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Association of multiple endocrine neoplasia type 2 and Hirschsprung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

V804M RET mutation and familial medullary thyroid carcinoma: report of a large family with expression of the disease only in the homozygous gene carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Familial medullary thyroid carcinoma associated with cutaneous lichen amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Pheochromocytoma: the expanding genetic differential diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Molecular genetic analysis of von Hippel-Lindau disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Clinical features of paraganglioma syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

PTEN hamartoma tumor syndrome: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Diffuse ganglioneuromatosis in small intestine associated with neurofibromatosis type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Acceptable age for prophylactic surgery in children with multiple endocrine neoplasia type 2a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Pheochromocytoma in multiple endocrine neoplasia type 2: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Multiple endocrine neoplasia type 2B--genetic basis and clinical expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

American Society of Clinical Oncology Policy Statement Update: Genetic Testing for Cancer Susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Diagnosis and management of medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Germline mutation of RET codon 883 in two cases of de novo MEN 2B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Minireview: RET: normal and abnormal functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

The RET receptor: function in development and dysfunction in congenital malformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Risk and Penetrance of Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 2A Families with Mutations at Codon 634 of the RET Proto-Oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

GermlineRETV804M mutation associated with multiple endocrine neoplasia type 2A

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D

Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318216CC6D